Chicago, July 23, 2024 - A recent panel discussion at the Association for American Cancer Institutesâ (AACI) Cancer Research Innovation (CRI) symposium highlighted a critical issue in clinical trials: the alarmingly high rates of error and non-compliance in imaging assessments.
The panel, hosted by Yunu, a provider of medical research technology and services, discussed a new abstract revealing that a staggering 50% of imaging assessments in active clinical trials displayed non-conformities. This finding was corroborated by two other panelists whose sites had implemented Yunuâs trial imaging platform, [www.yunu.io](https://www.yunu.io), and tracked their own results.
Three separate abstracts, employing similar methodologies, identified error rates ranging from 25% to 50% within their oncology clinical trial imaging endpoints. Notably, these error rates were successfully reduced to less than two percent after adopting Yunuâs platform.
The panel discussion and audience feedback underscored the widespread impact of imaging errors, leading to significant downstream consequences. These include:
Delayed Trial Activation: Errors in imaging assessments can hinder the efficient start of clinical trials.
Incorrect Patient Enrollment: Misinterpretation of images can lead to the enrollment of ineligible patients, compromising the validity of trial data.
Increased Costs: Errors result in additional resources and time dedicated to re-assessments and corrections, driving up overall trial expenses.
Audit Findings: Inconsistencies in imaging assessments can trigger audits and jeopardize trial integrity.
Data Loss: Errors can compromise the accuracy and reliability of valuable trial data.
The financial impact of these errors is substantial. A recent study revealed that the cost associated with imaging ineligible patients surpasses the total imaging expenses of the entire trial.
Yunu's platform aims to tackle these challenges head-on. The platform facilitates day-forward compliance for trial imaging, delivering significant efficiency gains for study staff (up to 80%), accelerating reading teams (by 50%), enabling seamless cross-site resource sharing, and ensuring audit-ready imaging data management. The platform also offers trial- and patient-level reporting, reader training and scheduling, and configurable dashboards for comprehensive oversight of all trials and sites.
Yunu's co-founder and CEO, Jeff Sorenson, emphasized the need for a robust solution, stating, âThe current model of in-house radiology research cores using inadequate tools and manual, error-prone processes has reached its breaking point. The data presented by the panelists clearly shows that imaging assessments cannot be conducted effectively in leading cancer centers, let alone in community oncology settings where 80% of Americans receive their care.â
With over 4,200 active clinical trials on the platform, data from 800 sponsors, including over 400 pharmaceutical companies, Yunu is transforming the landscape of imaging accuracy and efficiency. By maximizing visibility into early therapeutic signals and extending trials to broader and more diverse populations, Yunu is paving the way for a more robust and reliable future for clinical research.
About Yunu:
Yunu provides medical research technology and services to life sciences companies and clinical research environments specializing in precision imaging assessments. Committed to making breakthrough therapies accessible to everyone, Yunu unites medical imaging insights and connects clinical communities. With thousands of clinical trials relying on the platform daily, Yunu is setting a new standard for clinical trial imaging workflow. To learn more, visit [www.yunu.io](https://www.yunu.io).